Health Technology Assessment (HTA)
Health Technology Assessment (HTA) is a multidisciplinary process that uses explicit methods to determine a health technology’s value for healthcare decision-making. Attitudes towards HTA vary globally, with some countries using a variety of methods and analyses and others hardly any.
Around the World in HTAs: Saudi Arabia – Navigating the healthcare and HTA landscape
24 September 2025
Saudi Arabia’s healthcare system is undergoing major transformation under Vision 2030, reshaping regulation, funding and delivery models across the Kingdom. The introduction of a formal health technology assessment (HTA) framework and evolving reimbursement pathways are central to improving access to value-based healthcare.
Around the world in HTAs: China – From fragmentation to function
2 September 2025
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition Yawen Jiang, Meng Li and Claud Theakston take us to China.
Reflections from the Region: Healthcare transformation in the Middle East
18 June 2025
It’s not often that you witness a health system reinvent itself in real-time. And yet, this is precisely what is happening across the Middle East.
How Widely Are QALYs Used in OECD Countries? A Snapshot of International Practices
11 June 2025
As healthcare systems strive to allocate resources efficiently, the use of economic evaluation metrics like Quality-Adjusted Life Years (QALYs) has become increasingly important.
Around the world in HTAs: Argentina – Long Road to Institutionalizing HTA
9 June 2025
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Andrés Pichon-Riviere, Federico Augustovski, and Martina Garau take us to Argentina.
Around the World in HTAs: Kenya – Riding the Waves of Change
19 May 2025
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Angela Kairu and Edwine Barasa of the KEMRI Wellcome Trust Research Programme, and Paul Oyalo of OHE, take us to Kenya.
Understanding the Full Value of Long-Acting Therapies: less is more?
7 May 2025
Long-acting (LA) therapies represent a significant innovation in pharmaceutical development by offering a sustained drug effect with reduced administration frequency.
An Analysis of NICE’s Optimised Decisions from 2015 to 2024
1 May 2025
The National Institute for Health and Care Excellence (NICE) is the body responsible for recommending medicines for use within the National Health Service (NHS) in England.
